Carla Masini

Via Piero Maroncelli 40
Meldola, 47014, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

How Regulation 536/2014 Is Changing Academic Research with Therapeutic Radiopharmaceuticals: A Local Experience.

How Regulation 536/2014 Is Changing Academic Research with Therapeutic Radiopharmaceuticals: A Local Experience.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: October 13, 2025

A rare case report of relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type, treated with Epcoritamab: results obtained and lesson learned.

A rare case report of relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type, treated with Epcoritamab: results obtained and lesson learned.

Journal: Frontiers in oncology

Published: September 22, 2025

Production and Quality Control of [68Ga]Ga-FAPI-46: Development of an Investigational Medicinal Product Dossier for a Bicentric Clinical Trial.

Production and Quality Control of [68Ga]Ga-FAPI-46: Development of an Investigational Medicinal Product Dossier for a Bicentric Clinical Trial.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: August 27, 2025

Breast Immunology Network: Toward a Multidisciplinary and Integrated Model for Breast Cancer Care in Italy.

Breast Immunology Network: Toward a Multidisciplinary and Integrated Model for Breast Cancer Care in Italy.

Journal: Cancers

Published: July 14, 2025

Facts and figures of the compassionate use of onco-hematological drugs from 2016 to 2021: Results from the multicentric observational study Compass-O.

Facts and figures of the compassionate use of onco-hematological drugs from 2016 to 2021: Results from the multicentric observational study Compass-O.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: March 13, 2025

The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O.

The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O.

Journal: Clinical drug investigation

Published: July 02, 2024

New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact.

New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact.

Journal: Expert opinion on drug metabolism & toxicology

Published: May 23, 2024

Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).

Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).

Journal: Cancers

Published: April 15, 2024

Pharmacy Workload in Clinical Trial Management: A Preliminary Complexity Assessment Tool for Sponsored Oncology and Haematology Trials.

Pharmacy Workload in Clinical Trial Management: A Preliminary Complexity Assessment Tool for Sponsored Oncology and Haematology Trials.

Journal: Current oncology (Toronto, Ont.)

Published: April 04, 2024

Body weight and body surface area of adult patients with selected cancers: An Italian multicenter study.

Body weight and body surface area of adult patients with selected cancers: An Italian multicenter study.

Journal: PloS one

Published: March 22, 2024

A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).

A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).

Journal: Frontiers in oncology

Published: December 07, 2023

The descriptive epidemiology of melanoma in Italy has changed - for the better.

The descriptive epidemiology of melanoma in Italy has changed - for the better.

Journal: Italian journal of dermatology and venereology

Published: November 28, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026